Published in J Gastroenterol Hepatol on November 01, 2010
A systematic review and meta-analysis of randomized trials and prospective studies comparing covered and bare self-expandable metal stents for the treatment of malignant obstruction in the digestive tract. Int J Med Sci (2013) 0.90
Clinical outcomes of transjugular intrahepatic portosystemic shunt for portal hypertension: Korean multicenter real-practice data. Clin Mol Hepatol (2014) 0.90
Selection of a TIPS stent for management of portal hypertension in liver cirrhosis: an evidence-based review. World J Gastroenterol (2014) 0.89
Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications. World J Gastroenterol (2014) 0.88
Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis. World J Gastroenterol (2012) 0.86
Clinical Management of Chronic Portal/Mesenteric Vein Thrombosis: The Surgeon's Point of View. Viszeralmedizin (2014) 0.86
Long-term follow-up of TIPS created with expanded poly-tetrafluoroethylene covered stents. Dig Dis Sci (2013) 0.85
Using transjugular intrahepatic portosystemic shunts for complications of cirrhosis. Clin Gastroenterol Hepatol (2011) 0.85
Transjugular intrahepatic portosystemic shunt. Clin Liver Dis (2014) 0.84
Role of TIPS in Improving Survival of Patients with Decompensated Liver Disease. Int J Hepatol (2011) 0.83
Transjugular intrahepatic portosystemic shunt may be superior to conservative therapy for variceal rebleeding in cirrhotic patients with non-tumoral portal vein thrombosis: a hypothesis. Med Sci Monit (2012) 0.81
Historical overview and review of current day treatment in the management of acute variceal haemorrhage. World J Gastroenterol (2014) 0.79
Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with recurrent variceal hemorrhage. Gastroenterol Res Pract (2013) 0.79
Shunting branch of portal vein and stent position predict survival after transjugular intrahepatic portosystemic shunt. World J Gastroenterol (2014) 0.77
Efficacy of covered and bare stent in TIPS for cirrhotic portal hypertension: A single-center randomized trial. Sci Rep (2016) 0.77
Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open (2013) 0.76
Transjugular intrahepatic portosystemic shunt combined with esophagogastric variceal embolization in the treatment of a large gastrorenal shunt. World J Hepatol (2016) 0.75
Improving survival in patients with decompensated cirrhosis. J Gastroenterol Hepatol (2010) 0.75
Nationwide trends and predictors of inpatient mortality in 83884 transjugular intrahepatic portosystemic shunt. World J Gastroenterol (2016) 0.75
Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions. Gut Liver (2016) 0.75
Covered TIPS for secondary prophylaxis of variceal bleeding in liver cirrhosis: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) (2016) 0.75
The Evolution of Transjugular Intrahepatic Portosystemic Shunt: Tips. ISRN Hepatol (2014) 0.75
Predictive accuracy comparison of MELD and Child-Turcotte-Pugh scores for survival in patients underwent TIPS placement: a systematic meta-analytic review. Int J Clin Exp Med (2015) 0.75
EVS vs TIPS shunt for gastric variceal bleeding in patients with cirrhosis: A meta-analysis. World J Gastrointest Pharmacol Ther (2014) 0.75
Covered versus bare stents for transjugular intrahepatic portosystemic shunt: an updated meta-analysis of randomized controlled trials. Therap Adv Gastroenterol (2016) 0.75
TIPS versus endoscopic therapy for variceal rebleeding in cirrhosis: A meta-analysis update. J Huazhong Univ Sci Technolog Med Sci (2017) 0.75
Effect of initial stent position on patency of transjugular intrahepatic portosystemic shunt. World J Gastroenterol (2017) 0.75
Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell (2012) 5.16
miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer (2008) 4.09
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One (2009) 3.66
Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology (2013) 3.55
MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet (2010) 3.12
Hypoxia-inducible factor-1alpha induces Twist expression in tubular epithelial cells subjected to hypoxia, leading to epithelial-to-mesenchymal transition. Kidney Int (2009) 2.86
Hepatitis B in China. Lancet (2007) 2.67
De novo sequencing and analysis of the American ginseng root transcriptome using a GS FLX Titanium platform to discover putative genes involved in ginsenoside biosynthesis. BMC Genomics (2010) 2.41
Survival prediction of gastric cancer by a seven-microRNA signature. Gut (2009) 2.37
Local electronic properties of graphene on a BN substrate via scanning tunneling microscopy. Nano Lett (2011) 2.30
Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer (2008) 2.28
How to solve the crisis behind Bribegate for Chinese doctors. Lancet (2011) 2.27
Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: techniques, indications and results on 51 Chinese patients from a single centre. Liver Int (2013) 2.22
Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol (2010) 2.11
miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res (2011) 2.00
The third conformation of p38α MAP kinase observed in phosphorylated p38α and in solution. Structure (2010) 1.88
MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. Biochem Biophys Res Commun (2010) 1.80
The application of polyhydroxyalkanoates as tissue engineering materials. Biomaterials (2005) 1.78
Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res (2011) 1.68
Peripheral blood monocytes from patients with HBV related decompensated liver cirrhosis can differentiate into functional hepatocytes. Am J Hematol (2007) 1.66
Find duplicates among the PubMed, EMBASE, and Cochrane Library Databases in systematic review. PLoS One (2013) 1.63
Prevalence of covert duplicate publications in Budd-Chiari syndrome articles in China: a systematic analysis. Am J Med (2013) 1.63
Expression of seven main Rho family members in gastric carcinoma. Biochem Biophys Res Commun (2004) 1.63
Smartphone versus pen-and-paper data collection of infant feeding practices in rural China. J Med Internet Res (2012) 1.62
Electrostatic force microscopy on oriented graphite surfaces: coexistence of insulating and conducting behaviors. Phys Rev Lett (2006) 1.58
TRF2 promotes multidrug resistance in gastric cancer cells. Cancer Biol Ther (2006) 1.57
Effect of a novel inhibitory mAb against beta-subunit of F1F0 ATPase on HCC. Cancer Biol Ther (2008) 1.54
Epidemiology of venous thromboembolism in patients with liver diseases: a systematic review and meta-analysis. Intern Emerg Med (2014) 1.52
Effect of intravenous proton pump inhibitor regimens and timing of endoscopy on clinical outcomes of peptic ulcer bleeding. J Gastroenterol Hepatol (2012) 1.51
Reversal of multidrug resistance of gastric cancer cells by downregulation of TSG101 with TSG101siRNA. Cancer Biol Ther (2004) 1.51
MicroRNA let-7f inhibits tumor invasion and metastasis by targeting MYH9 in human gastric cancer. PLoS One (2011) 1.51
Transjugular intrahepatic portosystemic shunt in the treatment of Budd-Chiari syndrome: a critical review of literatures. Scand J Gastroenterol (2013) 1.50
Human mitochondrial Mrs2 protein promotes multidrug resistance in gastric cancer cells by regulating p27, cyclin D1 expression and cytochrome C release. Cancer Biol Ther (2009) 1.50
Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome: a systematic review. Eur J Gastroenterol Hepatol (2013) 1.49
Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci (2007) 1.48
PDGF signaling is required for epicardial function and blood vessel formation in regenerating zebrafish hearts. Proc Natl Acad Sci U S A (2010) 1.48
MicroRNA in colorectal cancer: from benchtop to bedside. Carcinogenesis (2010) 1.45
Overexpression of ZNRD1 promotes multidrug-resistant phenotype of gastric cancer cells through upregulation of P-glycoprotein. Cancer Biol Ther (2004) 1.44
Thrombotic risk factors in Chinese nonmalignant and noncirrhotic patients with portal vein thrombosis: an observational study with a systematic review of the literature. Eur J Gastroenterol Hepatol (2015) 1.43
Structure of a bacterial BLUF photoreceptor: insights into blue light-mediated signal transduction. Proc Natl Acad Sci U S A (2005) 1.43
Helicobacter pylori infection may improve the survival of patients with carcinomas. Med Hypotheses (2007) 1.40
Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology (2013) 1.39
Up-regulation of tumor suppressor genes might promote the malignant phenotype of cancer cells. Med Hypotheses (2007) 1.39
Two hypotheses for decreasing hepatic encephalopathy risk after transjugular intrahepatic portosystemic shunt. Hepatology (2010) 1.39
An ACAP1-containing clathrin coat complex for endocytic recycling. J Cell Biol (2007) 1.38
Electron beam emission from a diamond-amplifier cathode. Phys Rev Lett (2010) 1.38
QDMR: a quantitative method for identification of differentially methylated regions by entropy. Nucleic Acids Res (2011) 1.37
Astrocyte-derived ATP modulates depressive-like behaviors. Nat Med (2013) 1.35
Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol (2015) 1.33
p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int (2013) 1.31
MicroRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4. Carcinogenesis (2011) 1.30
Dysregulation of cellular signaling in gastric cancer. Cancer Lett (2010) 1.29
High-frequency generation of viable mice from engineered bi-maternal embryos. Nat Biotechnol (2007) 1.28
The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg (2010) 1.28
HHMD: the human histone modification database. Nucleic Acids Res (2009) 1.27
Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV1 expression. Hepatology (2014) 1.27
Micro-electrocardiograms to study post-ventricular amputation of zebrafish heart. Ann Biomed Eng (2009) 1.27
MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun (2013) 1.25
Cellular prion protein promotes invasion and metastasis of gastric cancer. FASEB J (2006) 1.23
Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma. J Hepatol (2012) 1.22